$0.40
+0.02 (+4.84%)
Open$0.40
Previous Close$0.39
Day High$0.43
Day Low$0.39
52W High$2.38
52W Low$0.27
Volume—
Avg Volume968.4K
Market Cap19.30M
P/E Ratio—
EPS$-1.21
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+9,862.9% upside
Current
$0.40
$0.40
Target
$40.32
$40.32
$26.90
$40.32 avg
$53.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.73M | 5.14M | 4.74M |
| Net Income | -102,176,432 | 951.6K | 665.5K |
| Profit Margin | -3,740.9% | 18.5% | 14.0% |
| EBITDA | -102,471,540 | 1.31M | 1.24M |
| Free Cash Flow | — | 380.5K | 530.0K |
| Rev Growth | — | -9.9% | +8.5% |
| Debt/Equity | 0.36 | 0.11 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |